Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis. 2019

Simona Lattanzi, and Gaetano Zaccara, and Fabio Giovannelli, and Elisabetta Grillo, and Raffaele Nardone, and Mauro Silvestrini, and Eugen Trinka, and Francesco Brigo
Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy.

Second and third generation AEDs have been directly compared to controlled-release carbamazepine (CBZ-CR) as initial monotherapy for new-onset focal epilepsy. Conversely, no head-to-head trials have been performed. The aim of this study was to estimate the comparative efficacy and tolerability of the antiepileptic monotherapies in adults with newly diagnosed focal epilepsy through a network meta-analysis (NMA). Randomized, double-blinded, parallel group, monotherapy studies comparing any AED to CBZ-CR in adults with newly diagnosed untreated epilepsy with focal-onset seizures was identified. The outcome measures were the seizure freedom for 6 and 12 months, the occurrence of treatment-emergent adverse events (TEAEs), and the treatment withdrawal due to TEAEs. Mixed treatment comparisons were conducted by a Bayesian NMA using the Markov chain Monte Carlo methods. Effect sizes were calculated as odds ratios (ORs) with 95% credible intervals (CrIs). Four trials were included involving 2856 participants, 1445 for CBZ-CR and 1411 for the comparative AEDs. Monotherapy AEDs compared to CBR-CR were levetiracetam (LEV), zonisamide (ZNS), lacosamide (LCM), and eslicarbazepine acetate (ESL). There were no statistical differences in the 6- and 12-month seizure freedom and TEAEs occurrence between LEV, ZNS, LCM, ESL, and CBZ-CR In the analysis of drug withdrawal due to TEAEs, LCM treatment was associated with a significantly lower discontinuation rate than CBZ-CR (OR 0.659, 95% CrI 0.428-0.950). LEV, ZNS, LCM, and ESL are effective initial monotherapy treatments in adult patients with newly diagnosed focal epilepsy and represent suitable alternatives to CBZ-CR.

UI MeSH Term Description Entries
D008297 Male Males
D004828 Epilepsies, Partial Conditions characterized by recurrent paroxysmal neuronal discharges which arise from a focal region of the brain. Partial seizures are divided into simple and complex, depending on whether consciousness is unaltered (simple partial seizure) or disturbed (complex partial seizure). Both types may feature a wide variety of motor, sensory, and autonomic symptoms. Partial seizures may be classified by associated clinical features or anatomic location of the seizure focus. A secondary generalized seizure refers to a partial seizure that spreads to involve the brain diffusely. (From Adams et al., Principles of Neurology, 6th ed, pp317) Abdominal Epilepsy,Digestive Epilepsy,Epilepsy, Focal,Epilepsy, Simple Partial,Focal Seizure Disorder,Gelastic Epilepsy,Partial Epilepsy,Partial Seizure Disorder,Seizure Disorder, Partial,Simple Partial Seizures,Amygdalo-Hippocampal Epilepsy,Benign Focal Epilepsy, Childhood,Benign Occipital Epilepsy,Benign Occipital Epilepsy, Childhood,Childhood Benign Focal Epilepsy,Childhood Benign Occipital Epilepsy,Epilepsy, Benign Occipital,Epilepsy, Localization-Related,Epilepsy, Partial,Occipital Lobe Epilepsy,Panayiotopoulos Syndrome,Partial Seizures, Simple, Consciousness Preserved,Rhinencephalic Epilepsy,Seizure Disorder, Focal,Subclinical Seizure,Uncinate Seizures,Abdominal Epilepsies,Amygdalo-Hippocampal Epilepsies,Benign Occipital Epilepsies,Digestive Epilepsies,Disorders, Focal Seizure,Disorders, Partial Seizure,Epilepsies, Abdominal,Epilepsies, Amygdalo-Hippocampal,Epilepsies, Benign Occipital,Epilepsies, Digestive,Epilepsies, Focal,Epilepsies, Gelastic,Epilepsies, Localization-Related,Epilepsies, Occipital Lobe,Epilepsies, Rhinencephalic,Epilepsies, Simple Partial,Epilepsy, Abdominal,Focal Epilepsies,Focal Epilepsy,Focal Seizure Disorders,Gelastic Epilepsies,Lobe Epilepsy, Occipital,Localization-Related Epilepsies,Localization-Related Epilepsy,Occipital Epilepsies, Benign,Occipital Epilepsy, Benign,Occipital Lobe Epilepsies,Partial Epilepsies,Partial Epilepsies, Simple,Partial Seizure Disorders,Partial Seizures, Simple,Rhinencephalic Epilepsies,Seizure Disorders, Focal,Seizure Disorders, Partial,Seizure, Subclinical,Seizure, Uncinate,Seizures, Simple Partial,Seizures, Subclinical,Seizures, Uncinate,Simple Partial Epilepsies,Subclinical Seizures,Uncinate Seizure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071076 Network Meta-Analysis Meta-analysis of randomized trials in which estimates of comparative treatment effects are visualized and interpreted from a network of interventions that may or may not have been evaluated directly against each other. Common considerations in network meta-analysis include conceptual and statistical heterogeneity and incoherence. Mixed Treatment Meta-Analysis,Multiple Treatment Comparison Meta-Analysis,Meta-Analyses, Mixed Treatment,Meta-Analyses, Network,Meta-Analysis, Mixed Treatment,Meta-Analysis, Network,Mixed Treatment Meta Analysis,Mixed Treatment Meta-Analyses,Multiple Treatment Comparison Meta Analysis,Network Meta Analysis,Network Meta-Analyses
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Simona Lattanzi, and Gaetano Zaccara, and Fabio Giovannelli, and Elisabetta Grillo, and Raffaele Nardone, and Mauro Silvestrini, and Eugen Trinka, and Francesco Brigo
November 2022, Brain and behavior,
Simona Lattanzi, and Gaetano Zaccara, and Fabio Giovannelli, and Elisabetta Grillo, and Raffaele Nardone, and Mauro Silvestrini, and Eugen Trinka, and Francesco Brigo
November 2020, Epilepsy research,
Simona Lattanzi, and Gaetano Zaccara, and Fabio Giovannelli, and Elisabetta Grillo, and Raffaele Nardone, and Mauro Silvestrini, and Eugen Trinka, and Francesco Brigo
December 2017, The Cochrane database of systematic reviews,
Simona Lattanzi, and Gaetano Zaccara, and Fabio Giovannelli, and Elisabetta Grillo, and Raffaele Nardone, and Mauro Silvestrini, and Eugen Trinka, and Francesco Brigo
June 2017, The Cochrane database of systematic reviews,
Simona Lattanzi, and Gaetano Zaccara, and Fabio Giovannelli, and Elisabetta Grillo, and Raffaele Nardone, and Mauro Silvestrini, and Eugen Trinka, and Francesco Brigo
April 2022, The Cochrane database of systematic reviews,
Simona Lattanzi, and Gaetano Zaccara, and Fabio Giovannelli, and Elisabetta Grillo, and Raffaele Nardone, and Mauro Silvestrini, and Eugen Trinka, and Francesco Brigo
November 2019, Epilepsia,
Simona Lattanzi, and Gaetano Zaccara, and Fabio Giovannelli, and Elisabetta Grillo, and Raffaele Nardone, and Mauro Silvestrini, and Eugen Trinka, and Francesco Brigo
April 2020, Journal of neurology,
Simona Lattanzi, and Gaetano Zaccara, and Fabio Giovannelli, and Elisabetta Grillo, and Raffaele Nardone, and Mauro Silvestrini, and Eugen Trinka, and Francesco Brigo
January 2017, The Lancet. Neurology,
Simona Lattanzi, and Gaetano Zaccara, and Fabio Giovannelli, and Elisabetta Grillo, and Raffaele Nardone, and Mauro Silvestrini, and Eugen Trinka, and Francesco Brigo
January 2023, Frontiers in neurology,
Simona Lattanzi, and Gaetano Zaccara, and Fabio Giovannelli, and Elisabetta Grillo, and Raffaele Nardone, and Mauro Silvestrini, and Eugen Trinka, and Francesco Brigo
January 2003, CNS drugs,
Copied contents to your clipboard!